These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25861318)

  • 21. Treatment of chronic delta hepatitis: a nine-year retrospective analysis.
    Gulsun S; Tekin R; Bozkurt F
    Hepat Mon; 2011 Sep; 11(9):731-5. PubMed ID: 22235216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience.
    Abbas Z; Memon MS; Mithani H; Jafri W; Hamid S
    Antivir Ther; 2014; 19(5):463-8. PubMed ID: 24423484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
    Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
    Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
    J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of adefovir dipivoxil and pegylated interferon alpha-2a treatment in chronic hepatitis B patients.
    Korkmaz P; Usluer G; Ozgunes I; Kartal ED; Erben N; Alpat SN
    North Clin Istanb; 2014; 1(1):26-32. PubMed ID: 28058298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis: a randomized trial.
    Canbakan B; Senturk H; Tabak F; Akdogan M; Tahan V; Mert A; Sut N; Ozaras R; Midilli K; Ozbay G
    J Gastroenterol Hepatol; 2006 Apr; 21(4):657-63. PubMed ID: 16677149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial.
    Abbas Z; Memon MS; Umer MA; Abbas M; Shazi L
    World J Hepatol; 2016 May; 8(14):625-31. PubMed ID: 27190579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir.
    Borzacov LM; de Figueiredo Nicolete LD; Souza LF; Dos Santos AO; Vieira DS; Salcedo JM
    Int J Infect Dis; 2016 May; 46():82-8. PubMed ID: 27005283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term interferon-alpha treatment of children with chronic hepatitis delta: a multicentre study.
    Di Marco V; Giacchino R; Timitilli A; Bortolotti F; Crivellaro C; Calzia R; Iannuzzi C; Prestileo T; Vajro P; Nebbia G; Stringhi C; Rosina F; Biassoni D; Callea F; Rizzetto M; Craxi A
    J Viral Hepat; 1996 May; 3(3):123-8. PubMed ID: 8871870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
    Gluhovschi C; Gadalean F; Kaycsa A; Curescu M; Sporea I; Gluhovschi G; Petrica L; Velciov S; Bozdog G; Bob F; Vernic C; Cioca D
    Immunopharmacol Immunotoxicol; 2011 Dec; 33(4):744-50. PubMed ID: 21320001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long term efficacy of pegylated ınterferone in the treatment of delta hepatitis: a single center experience.
    Kılıç ZM; Köksal AS; Kalkan IH; Suna N; Yıldız H; Kacar S
    Acta Gastroenterol Belg; 2016; 79(2):329-335. PubMed ID: 27821029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b.
    Erhardt A; Gerlich W; Starke C; Wend U; Donner A; Sagir A; Heintges T; Häussinger D
    Liver Int; 2006 Sep; 26(7):805-10. PubMed ID: 16911462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term follow up of peginterferon-α-2a treatment of hepatitis B e-antigen (HBeAg) positive and HBeAg negative chronic hepatitis B patients in phase II and III studies.
    Okanoue T; Shima T; Hasebe C; Karino Y; Imazeki F; Kumada T; Minami M; Imai Y; Yoshihara H; Mita E; Morikawa T; Nishiguchi S; Kawakami Y; Nomura H; Sakisaka S; Kurosaki M; Yatsuhashi H; Oketani M; Kohno H; Masumoto A; Ikeda K; Kumada H
    Hepatol Res; 2016 Sep; 46(10):992-1001. PubMed ID: 26670363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy.
    Lutterkort GL; Wranke A; Hengst J; Yurdaydin C; Stift J; Bremer B; Hardtke S; Keskin O; Idilman R; Manns MP; Dienes HP; Falk C; Wedemeyer H; Heidrich B
    J Viral Hepat; 2018 Nov; 25(11):1384-1394. PubMed ID: 29888837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon-α for patients with chronic hepatitis delta: a systematic review of randomized clinical trials.
    Lamers MH; Kirgiz ÖÖ; Heidrich B; Wedemeyer H; Drenth JP
    Antivir Ther; 2012; 17(6):1029-37. PubMed ID: 22892440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pegylated interferon alpha 2a in treating chronic hepatitis B patients].
    Tian YL; Zhao W; Shen L; Liu W; Chang JB; Fang ZX; Yin WW; Wang L; Sun XB; Yang YJ
    Zhonghua Gan Zang Bing Za Zhi; 2006 Nov; 14(11):806-10. PubMed ID: 17125604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta.
    Wranke A; Hardtke S; Heidrich B; Dalekos G; Yalçin K; Tabak F; Gürel S; Çakaloğlu Y; Akarca US; Lammert F; Häussinger D; Müller T; Wöbse M; Manns MP; Idilman R; Cornberg M; Wedemeyer H; Yurdaydin C
    J Viral Hepat; 2020 Dec; 27(12):1359-1368. PubMed ID: 32707605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strain-specific responsiveness of hepatitis D virus to interferon-alpha treatment.
    Giersch K; Perez-Gonzalez P; Hendricks L; Goldmann N; Kolbe J; Hermanussen L; Bockmann JH; Volz T; Volmari A; Allweiss L; Petersen J; Glebe D; Lütgehetmann M; Dandri M
    JHEP Rep; 2023 Apr; 5(4):100673. PubMed ID: 36908749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation.
    Jones J; Shepherd J; Baxter L; Gospodarevskaya E; Hartwell D; Harris P; Price A
    Health Technol Assess; 2009 Jul; 13(35):1-172, iii. PubMed ID: 19607759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the efficacy of 12 months and longer courses of interferon therapy for the treatment of chronic delta hepatitis: a retrospective cohort study.
    Soyer OM; Baran B; Ormeci AC; Gokturk S; Aydın E; Onel D; Gulluoglu M; Karaca C; Akyuz F; Demir K; Besisik F; Kaymakoglu S
    Postgrad Med; 2016 May; 128(4):432-8. PubMed ID: 27054544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.